Incyte | INCY - Sales Revenues


Incyte reported $1.27B in Sales Revenues for its fiscal quarter ending in March of 2026.





Sales Change Date
Acadia Pharmaceuticals USD 268.06M 15.94M Mar/2026
Agenus USD 34.2M 3.97M Dec/2025
Agios Pharmaceuticals USD 18.8M 1.17M Mar/2026
Alnylam Pharmaceuticals USD 1.17B 70M Mar/2026
Amgen USD 8.62B 1.28B Mar/2026
BioCryst Pharmaceuticals USD 406.56M 247.16M Dec/2025
Biogen USD 2.25B 30M Mar/2026
BioMarin Pharmaceutical USD 766M 109M Mar/2026
Bristol-Myers Squibb USD 11.49B 1.01B Mar/2026
Eli Lilly USD 19.8B 500M Mar/2026
Exelixis USD 610.8M 12.14M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Ionis Pharmaceuticals USD 246M 43M Mar/2026
MacroGenics USD 20.8M 20.43M Mar/2026
Merck USD 16.29B 110M Mar/2026
Moderna USD 389M 289M Mar/2026
Nektar Therapeutics USD 21.81M 2.32M Dec/2025
Neurocrine Biosciences USD 811M 5.5M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Novartis USD 13.11B 750M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
PTC Therapeutics USD 273M 108.3M Mar/2026
Puma Biotechnology USD 80.54M 33.46M Sep/2024
Regeneron Pharmaceuticals USD 3.6B 280M Mar/2026
Sarepta Therapeutics USD 730.8M 287.9M Mar/2026
Ultragenyx Pharmaceutical USD 136M 71M Mar/2026
Vertex Pharmaceuticals USD 2.99B 200M Mar/2026